All In MedTech

FDA Clearance Tracker · P200010-S032

Guardant360® CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 7, 2026

Approved

Time to decision

28 days

Received Jul 10, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P200010-S032
Device name
Guardant360® CDx
Applicant location
Redwood City, CA
Received
Jul 10, 2026
Decided
Aug 7, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P200010

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval of the clinical protocol titled “Clinical Validation of Guardant360 CDx for the Selection of First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with ERBB2/HER2 TKD-Activating Mutations for Zongertinib Therapy” (Protocol No. 01-LU-038, PLP-003941 R1, Version 1.0) for the post-approval study.

Source documents

Other decisions for Guardant Health, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.